Trastuzumab
- PDF / 169,122 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 61 Downloads / 150 Views
1 S
Cardiotoxicity manifesting as decline in ejection fraction: 2 case reports In a study of 100 patients treated with trastuzumab from 2011 to 2014, two patients [ages and sexes not stated] were described, who developed cardiotoxicity manifesting as decline in ejection fraction during treatment with trastuzumab for metastatic breast cancer [routes, dosages, time to reaction onsets and outcomes not stated]. The patients, who were diagnosed with metastatic breast cancer, started receiving first line treatment with trastuzumab. One patient was a smoker and the other patient received concurrent unspecified hormone replacement therapy. Subsequently, echocardiogram revealed significant decline in ejection fraction in both patients. Both patients were diagnosed with cardiotoxicity manifesting as decline in ejection fraction secondary to trastuzumab therapy. Sherman S, et al. Cardiotoxicity manifestations in metastatic breast cancer patients treated with trastuzumab as first line. Journal of Clinical Oncology 38: No. 15, 2020. 803503172 Available from: URL: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13011 [abstract]
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...
